| Project/Area Number |
15K09173
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
OKA YOSHIHIRO 大阪大学, 医学系研究科, 寄附講座教授 (20273691)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
武田 吉人 大阪大学, 医学系研究科, 助教 (40452388)
大塚 倫之 大阪大学, 医学部附属病院, 特任助教(常勤) (20730576)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | WT1 / ペプチドワクチン / 癌抗原 / 癌免疫療法 / 胸部悪性腫瘍 / 免疫療法 / 胸腺悪性腫瘍 / バイオマーカー / 肺癌 / 胸腺腫瘍 / 癌免疫動態 |
|---|
| Outline of Final Research Achievements |
Analysis of immune response against cancer, focused on cancer antigen WT1-specific immune response, was performed, aiming at the development of WT1 peptide-based immunotherapy for malignancies including those in the respiratory medicine field.
We succeeded in gene cloning of T cell receptor of mouse WT1-specific cytotoxic T lymphocytes. This achievement provided the molecular basis for the mouse in vivo experiment system to analyze WT1-specific immunity, which we had established previously. Based on cDNA microarray analysis of blood samples, Syndecan-4 was shown to be a biomarker to predict clinical outcome of patients with glioblastoma multiforme treated by WT1 vaccine. It was shown that WT1 peptide vaccination induces not only WT1-specific cellular immunity but also WT1-specific antibody. Successful results of clinical studies of WT1 peptide vaccine, including those for thymic malignancies, pancreas cancer, and acute myeloid leukemia, were obtained.
|
